The immune modifying effects of chemotherapy and advances in chemo-immunotherapy

DR Principe, SD Kamath, M Korc, HG Munshi - Pharmacology & …, 2022 - Elsevier
Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for several
malignancies. While the use of single-agent or combined ICIs has achieved acceptable …

Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer

H Zhang, L Ye, X Yu, K **, W Wu - Frontiers in Immunology, 2022 - frontiersin.org
Pancreatic cancer has an exclusive inhibitory tumor microenvironment characterized by a
dense mechanical barrier, profound infiltration of immunosuppressive cells, and a lack of …

[HTML][HTML] Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer

Y Ma, J Li, H Wang, Y Chiu, CV Kingsley, D Fry… - Gastroenterology, 2020 - Elsevier
Background & Aims Advanced pancreatic ductal adenocarcinoma (PDAC) is resistant to
therapy, including immune checkpoint inhibitors. We evaluated the effects of a neutralizing …

Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer

IV Zurlo, M Schino, A Strippoli, MA Calegari… - Cancer Immunology …, 2022 - Springer
The combination of perioperative chemotherapy plus complete surgical resection is currently
accounted as the first-choice strategy in patients with locally advanced Gastric Cancer …

Prognostic impact of tumor-infiltrating lymphocytes and neutrophils on survival of patients with upfront resection of pancreatic cancer

RC Miksch, MB Schoenberg, M Weniger, F Bösch… - Cancers, 2019 - mdpi.com
In patients with pancreatic ductal adenocarcinoma (PDAC), the tumor microenvironment
consists of cellular and stromal components that influence prognosis. Hence, tumor …

Pancreatic ductal adenocarcinoma: molecular pathology and predictive biomarkers

M Taherian, H Wang, H Wang - Cells, 2022 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis due to the lack
of methods or biomarkers for early diagnosis and its resistance to conventional treatment …

Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients

SA Lim, J Kim, S Jeon, MH Shin, J Kwon… - Frontiers in …, 2019 - frontiersin.org
Tumor-infiltrating lymphocytes (TILs), found in patients with advanced pancreatic ductal
adenocarcinoma (PDAC), are shown to correlate with overall survival (OS) rate. Although …

Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of protumorigenic immune cells

C Mota Reyes, S Teller, A Muckenhuber… - Clinical Cancer …, 2020 - AACR
Purpose: Neoadjuvant therapy (neoTx) has dramatically improved the prognosis of patients
with locally advanced and borderline resectable pancreatic ductal adenocarcinoma, yet its …

Interactions between cancer-associated fibroblasts and T cells in the pancreatic tumor microenvironment and the role of chemokines

L Gorchs, H Kaipe - Cancers, 2021 - mdpi.com
Simple Summary Despite advances in therapeutic modalities, the five-year overall survival
for pancreatic cancer is still less than 10%. Pancreatic tumors are characterized by a highly …

NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype

F Marcon, J Zuo, H Pearce, S Nicol… - …, 2020 - Taylor & Francis
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common tumor subtypes and
remains associated with very poor survival. T cell infiltration into tumor tissue is associated …